Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0675
Bid: 0.065
Ask: 0.07
Change: -0.0025 (-3.57%)
Spread: 0.005 (7.692%)
Open: 0.07
High: 0.07
Low: 0.0675
Prev. Close: 0.07
RBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Gain

14 Feb 2006 07:01

Adventis Group PLC14 February 2006 For release 07.00am 14 February 2006 Adventis Group plc Contract Gain Adventis, the specialist multimedia marketing and advertising agency, announcesthat Affiniti (UK) Ltd, its Bucks-based healthcare agency has been awarded theZanidip account following a three-way pitch. The contract, for an undisclosedamount, is now live. Zanidip (lercanidipine), a highly effective calcium blocker used by GP's tolower blood pressure in the treatment of hyper tension, was originally licensedout but the Italian multi-national pharmaceutical group Recordati S.p.A. has nowopened a UK marketing office and will henceforward market the drug itself. Highblood pressure is a problem most common in the elderly, related to poor controlof the working of the heart, and for kidney and liver diseases. Although Affiniti has been involved before in marketing the Zanidip brand,Recordati were looking for a completely fresh approach to move the productforward. Martin Symons, Recordati's UK General Manager, commented: "It was by no means aforegone conclusion for Affiniti - they had to perform on an even playing fieldagainst good competitors, but they came through very strongly. We look forwardto working with them to develop a strong campaign that will move Zanidip to itsrightful position in the marketplace." Affiniti has also won three other pitches against major league competition: - A major product launch for MabThera in severe rheumatoid arthritis for Roche - A major new European campaign in glaucoma for Allergan's Lumigan - A new campaign for Periostat, a dental root treatment for Alliance Said Affiniti's Managing Director, Stuart Tennant: "Across all these recentpitches we have been up against some of the UK's leading healthcare agencieswith big creative reputations - so we know we can compete at the top level. Weare continuing to build our team, our clients' brands - and a strong reputationof our own." - ENDS - Editor's Notes Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its six operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 80 staff in London and the South East. www.adventis.co.uk Recordati is a European pharmaceutical group mainly dedicated to the research,development, manufacturing and marketing of pharmaceuticals. Headquartered inMilan, it has operations in France, Germany, Greece, Ireland, Italy, Spain,Switzerland, the United Kingdom and the United States. Recordati has been listedon the Italian Stock Exchange since 1984. www.recordati.com Enquiries: Affiniti (UK) LtdStuart Tennant, Managing Director 01494 775 213 Adventis Group plc Charles Phillpot, Chief Executive Officer 020 7034 4750 Seymour PierceJohn Depasquale 020 7107 8000 Binns & Co PR Ltd 020 7786 9600Peter Binns / 07768 392 582Annie Evangeli 07778 507 162 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 20247:00 amRNSChange of Broker
2nd May 20247:00 amRNSHoA Signed between Gunvor and LNEnergy
27th Feb 20247:00 amRNSOperational and Corporate Update
20th Feb 20247:00 amRNSInvestor Presentation
18th Jan 20247:00 amRNSNotification of final tranche of Shell payment
11th Jan 20247:00 amRNSTransaction in Own Shares
10th Jan 202411:47 amRNSResult of Requisitioned General Meeting
10th Jan 20247:00 amRNSTransaction in Own Shares
9th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20247:00 amRNSTransaction in Own Shares
5th Jan 20247:00 amRNSTransaction in Own Shares
4th Jan 20243:40 pmRNSUpdate re Requisitioned General Meeting
4th Jan 20247:00 amRNSTransaction in Own Shares
3rd Jan 20247:00 amRNSTransaction in Own Shares
2nd Jan 20247:00 amRNSTransaction in Own Shares
29th Dec 20237:00 amRNSGlass Lewis Recommendation
29th Dec 20237:00 amRNSTransaction in Own Shares
28th Dec 20237:00 amRNSUpdate re Requisitioned General Meeting
28th Dec 20237:00 amRNSTransaction in Own Shares
27th Dec 202311:03 amRNSTransaction in Own Shares
22nd Dec 20237:00 amRNSISS Supports the Board of Reabold
22nd Dec 20237:00 amRNSTransaction in Own Shares
21st Dec 20237:07 amRNSTransaction in Own Shares
20th Dec 20237:00 amRNSTransaction in Own Shares
20th Dec 20237:00 amRNSEnvironmental Impact Study Filed for Colle Santo
19th Dec 20237:00 amRNSTransaction in Own Shares
18th Dec 20237:00 amRNSTransaction in Own Shares
15th Dec 20237:00 amRNSTransaction in Own Shares
14th Dec 20237:00 amRNSTransaction in Own Shares
13th Dec 20237:01 amRNSRecommencement of Share Buyback Programme
13th Dec 20237:00 amRNSPublication of Circular
11th Dec 20237:00 amRNSFurther Investment into LNEnergy
7th Dec 20233:42 pmRNSHolding(s) in Company
5th Dec 20237:00 amRNS£5.2 million received for the sale of Corallian
1st Dec 20237:00 amRNSItalian Government Decree on Energy Sector
22nd Nov 20235:10 pmRNSRequisition of General Meeting
17th Nov 20237:00 amRNSFurther Investment into LNEnergy
14th Nov 20237:00 amRNSPurported Requisition of General Meeting
8th Nov 202310:50 amRNSRequisition of General Meeting
3rd Nov 20234:10 pmRNSResponse to Media Reporting
3rd Nov 20234:02 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSUnaudited Interim Results
27th Sep 20237:00 amRNSApproval for EA Permit at West Newton
12th Sep 20237:00 amRNSFurther Investment into LNEnergy
5th Sep 20237:00 amRNSColle Santo Project Enters Operational Phase
7th Aug 20237:00 amRNSUpdate on LNEnergy and the Colle Santo gas field
24th Jul 202312:24 pmRNSHolding(s) in Company
21st Jul 20237:00 amRNSTransaction in Own Shares
19th Jul 20237:00 amRNSTransaction in Own Shares
18th Jul 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.